Driving research of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS),
Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia and Post COVID .

OMF Linda Tannenbaum

Linda Tannenbaum is the Founder and CEO/President of Open Medicine Foundation. Linda founded OMF after her 16-year-old daughter came down with sudden onset ME / CFS in 2006. She was told there was no diagnostic test or treatment for the devastating disease that was preventing her daughter from leaving her bed and living her life.

After researching options, Linda realized that open, global collaborative research into the disease was terribly lacking, as was the funding of research, so she established OMF in 2012 to fundraise and facilitate large-scale research in search of diagnostic tools, treatments, and ultimately prevention for ME / CFS and related chronic complex diseases.

Linda is a clinical laboratory scientist with a degree in bacteriology from UCLA. She ran and was part-owner of a clinical laboratory for over 20 years. Her passion today is finding a cure for these chronic complex diseases — giving the millions suffering their lives back —  and improving clinical care for patients.

KimberlyHicks

Ms. Hicks has worked with OMF as a board member since 2014, has served in an interim capacity as the CFO/COO, and has joined the team full-time.  She is a C-suite Finance industry veteran with over 25 years of leadership, business transformation, business development/sales, merger integrations, and major strategic initiative experience across private and public sectors, and international settings.  In the past few years she has transitioned to Health Tech and Healthcare, and has a keen interest and passion for the use of technology to solve big healthcare problems. Ms. Hicks holds an MA in Industrial/Organizational Psychology from St. Mary’s University and a BA in Psychology from The University of Texas.

PatriciaLinsley

Ms. Linsley is a senior vice president of Crescent Capital Group LP. She is responsible for directing Crescent’s charitable giving activities. She is also responsible for coordinating Crescent’s annual Partners Conference. Before taking this role in the company, she managed the Human Resources department for 24 years.

Prior to joining the Crescent team, Ms. Linsley worked in the International Capital Markets Group and High Yield Bond Department of Drexel Burnham Lambert, Inc. Ms. Linsley studied Business Administration at Mesa College in California.

K Bach headshot (1)

Katie has spent her career in a range of strategy and leadership roles in both the for-profit and non-profit sector. She is currently the Managing Director of the Good Jobs Institute, a non-profit dedicated to helping companies thrive by creating good jobs. Prior to joining the Good Jobs Institute, Katie was a Director of Global Strategy at Starbucks, where she led the development of the company’s annual strategic plan and served as an internal consultant. Previously, she spent nearly five years in management consulting, first with McKinsey & Company and then at a Nairobi-based firm, advising clients on strategy, organizational structure, and human capital management. While at McKinsey, Katie was also on the founding team of Generation, McKinsey’s global youth employment program. Before business school, Katie spent three years working at the World Bank, managing post-conflict programs in West Africa.

Katie has an undergraduate degree in Politics, Philosophy, and Economics from the University of Oxford. She was valedictorian of her Master’s program in Global Politics at the London School of Economics, and received her MBA from MIT Sloan School of Management. At MIT Sloan, she won a Siebel Scholarship, McKinsey Award, and Forte Fellowship, all for outstanding academic and leadership contributions. Katie lives outside of Boston with her husband and dog.

DeborahRose

Dr. Rose is a psychiatrist in private practice in Palo Alto, California. She has over 40 years of experience in treating posttraumatic stress disorder, both acute PTSD and complex PTSD. She has developed and published a model for psychodynamic psychotherapy of PTSD and has published articles and book chapters on these subjects. She has taught extensively for professionals and for the lay public and has consulted to the National Centers for PTSD.

Dr. Rose’s interest in serving on our board stems from both her personal experience of having fibromyalgia and then Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS), and also from having patients in her practice with these illnesses. She is very excited about the pending revolutionary research and about current interventions that have brought her and her patients notable relief.

Rabbi Shai Held

Rabbi Shai Held–theologian, scholar, and educator–is President, Dean, and Chair in Jewish Thought at Hadar, where he also directs the Center for Jewish Leadership and Ideas.  Previously, he served for six years as Scholar-in-Residence at Kehilat Hadar in New York City, and taught both theology and Halakhah at the Jewish Theological Seminary.  He also served as Director of Education at Harvard Hillel.

A 2011 recipient of the prestigious Covenant Award for excellence in Jewish education, Rabbi Held has been named multiple times to Newsweek’s list of the 50 most influential rabbis in America.  He holds a doctorate in religion from Harvard; his main academic interests are in modern Jewish and Christian thought, in biblical theology, and in the history of Zionism.  Rabbi Held’s first book, Abraham Joshua Heschel: The Call of Transcendence, was published by Indiana University Press in 2013; The Heart of Torah, a collection of essays on the Torah in two volumes, was published by JPS in 2017.

Hany Zayed 2

Hany Zayed, Ph.D. is the head of Data Science Solutions group at Rigel Pharmaceuticals. He has more than 25 years of experience in development of novel treatments. He has special research interest in the development of novel treatments and therapeutics of rare and orphan indications. Prior to joining Rigel, he was the Head of Biometrics at AbbVie Stemcentrx, XOMA and Nektar Therapeutics where he played vital roles in the development and regulatory approval of novel treatments in various therapeutic areas including oncology, hematology and immunology to US and European patients. He received a Ph.D. in Biostatistics in 2001.

Emeritus

RPChanningRodgers

R.P. Channing Rodgers is currently a professor at UCSF with a focus on informatics research and training.

Previously, he was a clinical officer at the FDA in the office of Orphan Product Development, where he leveraged informatics to identify overlooked therapies for rare diseases, created a network-based course for small clinical trials, and reviewed grant and orphan drug applications.

Dr. Rodgers joined the FDA from the NIH, where he had the distinction of being the first physician to actively develop biomedical applications for the Web. At the NIH, he was the founding chair of the National Science Foundation’s Web Consortium, and he co-created the first large catalogued image archive for the Web and devised and directed an Internet-based multimedia course: “The Science of Small Clinical Trials.”

Dr. Rodgers received training at Harvard College and the University of Utah College of Medicine. He received postdoctoral training at the University of London, NCI’s Laboratory of Theoretical Biology, and the International Institute of Cellular and Molecular Pathology (Brussels). He completed training in Clinical Pathology within the Department of Laboratory Medicine in the School of Medicine at the University of California, San Francisco. Dr. Rodgers has published extensively and was formerly the editor-in-chief of the journal Computers in Biology and Medicine.

Stay Informed

Be the first to hear our research news.

Subscribe Now.

No thanks

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

 

Averting a second pandemic:

Open Medicine Foundation leads groundbreaking international study of

Long COVID’s conversion to ME/CFS

AGOURA HILLS, CALIF.  — Open Medicine Foundation (OMF) is leading a large-scale international collaborative study investigating the potential conversion of Post-Acute Sequelae SARS-CoV-2 infection — more commonly known as Long COVID or Post-COVID Syndrome —  to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a chronic, life-altering disease with no known cause, diagnostic test or FDA approved treatments available.

Up to 2.5 million people in the U.S. alone suffer from ME/CFS; the COVID-19 pandemic could at least double that number. An estimated 35 percent of Americans who had COVID-19 have failed to fully recover several months after infection, prompting many to call it “a potential second pandemic.”

OMF recognized a familiar health crisis emerging, one with eerie similarities to ME/CFS. This crisis presented a unique opportunity to understand how a viral infection — in this case COVID-19 — may develop into ME/CFS in some patients. The goal is to find targeted treatments for ME/CFS patients and ultimately prevent its onset in people infected with SARS-CoV-2 or other infections.

The federal government is only now investing in Post-COVID research, with no focus on its connection to ME/CFS. OMF has already engaged researchers for the largest-scale study of its kind, solely supported by private donors who have contributed over one million dollars to date. When fully funded, the five million dollar, three-year study will be conducted across the globe at OMF funded Collaborative Research Centers, led by some of the world’s top researchers and ME/CFS experts.

BACKGROUND

In a significant percentage of patients, infections preceded their development of ME/CFS.  For example, according to the CDC about one in ten infected with Epstein-Barr virus, Ross River virus, or Coxiella burnetti develop symptoms that meet the criteria for ME/CFS.

THE STUDY

The ability to follow the development of ME/CFS from a known viral infection is unprecedented to date and crucial to researchers’ understanding of the disease. The focus of this study is to find the biological differences between persons returning to good health after COVID-19 and persons who remained ill more than six months after infection and developed ME/CFS.  Understanding these alterations in key pathways can lead to groundbreaking discoveries including new biomarkers, drug targets, and prevention and treatment strategies.

###

About Open Medicine Foundation

Established in 2012, Open Medicine Foundation leads the largest, concerted worldwide nonprofit effort to diagnose, treat, and prevent ME/CFS and related chronic, complex diseases such as Post Treatment Lyme Disease Syndrome, Fibromyalgia, and Post COVID. OMF adds urgency to the search for answers by driving transformational philanthropy into global research. We have raised over $28 Million from private donors and facilitated and funded the establishment of five prestigious ME/CFS Collaborative Research Centers around the world. To learn more, visit www.omf.ngo.

CONTACT:

Heather Ah San

Development and Communications Manager

1-650-242-8669

heather@omf.ngo